Support Care Cancer (2018) 26:1169–1179 https://doi.org/10.1007/s00520-017-3938-7 ORIGINAL ARTICLE A survey of patient and physician acceptance of skin toxicities from anti-epidermal growth factor receptor therapies 1 1 2 2 Bernd Tischer & Martina Bilang & Matthias Kraemer & Philippe Ronga & Mario E. Lacouture Received: 20 July 2017 /Accepted: 23 October 2017 /Published online: 7 November 2017 The Author(s) 2017. This article is an open access publication Abstract causing pain, impairing quality of life, and proving difficult Background Inhibition of the epidermal growth factor recep- to manage. Despite these negative influences, the majority of tor (EGFR) extends patient survival in multiple tumor types. patients (71%) indicated they were willing to accept skin tox- Skin toxicities are the most common adverse event (AE) elic- icities as an AE of an effective therapy. Indeed, the majority of ited by EGFR inhibitors. Here, we provide deeper insights patients and physicians preferred a more effective therapy that into patients’ and physicians’ acceptance of the risk/benefit induces more severe skin toxicities than a less efficacious trade-offs of skin toxicities during cancer therapy, including therapy that induces less severe skin toxicities; interestingly, comparison of their perceptions and experiences with derma- patients were willing to accept a
Supportive Care in Cancer – Springer Journals
Published: Nov 7, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera